IDYA - Latest News
IDEAYA Biosciences, Inc. (IDYA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $3.49B. Beta to the broader market is -0.05.
The article list below shows the most recent IDYA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IDYA Headlines
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com - Jun 26, 2026
SOUTH SAN FRANCISCO, Calif. , June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc.
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
prnewswire.com - Jun 17, 2026
SOUTH SAN FRANCISCO, Calif. , June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc.
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
prnewswire.com - Jun 15, 2026
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties I
Ideaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026
seekingalpha.com - Jun 11, 2026
IDEAYA Biosciences maintains a "Strong Buy" rating, driven by positive darovasertib data in uveal melanoma and robust clinical progress. The company'
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
prnewswire.com - Jun 10, 2026
SOUTH SAN FRANCISCO, Calif. , June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc.
How News Affects IDYA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IDYA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IDYA news questions
- What is the latest IDYA news headline?
- The most recent IDYA headline (Jun 26, 2026) is "IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IDYA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IDYA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IDYA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.